QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
NASDAQ:PTGX

Protagonist Therapeutics - PTGX Stock Forecast, Price & News

$14.46
+0.40 (+2.84%)
(As of 02/2/2023 12:00 AM ET)
Add
Compare
Today's Range
$14.04
$14.76
50-Day Range
$7.36
$14.06
52-Week Range
$6.91
$29.62
Volume
1.55 million shs
Average Volume
995,971 shs
Market Capitalization
$711.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.50

Protagonist Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
127.1% Upside
$32.50 Price Target
Short Interest
Healthy
4.66% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.60) to ($3.01) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.00 out of 5 stars

Medical Sector

606th out of 1,030 stocks

Pharmaceutical Preparations Industry

307th out of 502 stocks


PTGX stock logo

About Protagonist Therapeutics (NASDAQ:PTGX) Stock

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Receive PTGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PTGX Stock News Headlines

Protagonist Therapeutics (NASDAQ:PTGX) Trading 3.6% Higher
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Profit From the Commercial Solar Boom?
Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered.
PTGX Protagonist Therapeutics, Inc.
See More Headlines
Receive PTGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PTGX Company Calendar

Last Earnings
11/08/2022
Today
2/02/2023
Next Earnings (Estimated)
2/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PTGX
Fax
N/A
Employees
118
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$32.50
High Stock Price Forecast
$41.00
Low Stock Price Forecast
$21.00
Forecasted Upside/Downside
+124.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-125,550,000.00
Net Margins
-291.70%
Pretax Margin
-369.64%

Debt

Sales & Book Value

Annual Sales
$27.36 million
Book Value
$6.29 per share

Miscellaneous

Free Float
46,591,000
Market Cap
$711.43 million
Optionable
Not Optionable
Beta
2.11

Key Executives

  • Dinesh V. PatelDinesh V. Patel
    President, Chief Executive Officer & Director
  • Asif Ali
    Chief Financial Officer & Executive Vice President
  • Mark L. Smythe
    Vice President-Technology
  • Samuel R. Saks
    Chief Medical Officer
  • Arturo Molina
    Chief Medical Officer













PTGX Stock - Frequently Asked Questions

Should I buy or sell Protagonist Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PTGX shares.
View PTGX analyst ratings
or view top-rated stocks.

What is Protagonist Therapeutics' stock price forecast for 2023?

4 analysts have issued 1 year target prices for Protagonist Therapeutics' shares. Their PTGX share price forecasts range from $21.00 to $41.00. On average, they predict the company's stock price to reach $32.50 in the next twelve months. This suggests a possible upside of 123.7% from the stock's current price.
View analysts price targets for PTGX
or view top-rated stocks among Wall Street analysts.

How have PTGX shares performed in 2023?

Protagonist Therapeutics' stock was trading at $10.91 at the beginning of 2023. Since then, PTGX shares have increased by 33.2% and is now trading at $14.53.
View the best growth stocks for 2023 here
.

When is Protagonist Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our PTGX earnings forecast
.

How were Protagonist Therapeutics' earnings last quarter?

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) announced its quarterly earnings results on Tuesday, November, 8th. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.94) by $0.30. Protagonist Therapeutics had a negative trailing twelve-month return on equity of 46.74% and a negative net margin of 291.70%.

What other stocks do shareholders of Protagonist Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Protagonist Therapeutics investors own include VBI Vaccines (VBIV), Viking Therapeutics (VKTX), ImmunoGen (IMGN), SCYNEXIS (SCYX), Energy Transfer (ET), Strongbridge Biopharma (SBBP), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX) and Sorrento Therapeutics (SRNE).

When did Protagonist Therapeutics IPO?

(PTGX) raised $70 million in an initial public offering on Thursday, August 11th 2016. The company issued 5,800,000 shares at a price of $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets acted as the underwriters for the IPO.

What is Protagonist Therapeutics' stock symbol?

Protagonist Therapeutics trades on the NASDAQ under the ticker symbol "PTGX."

Who are Protagonist Therapeutics' major shareholders?

Protagonist Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Gratus Capital LLC (0.45%), Dupont Capital Management Corp (0.03%), Zurcher Kantonalbank Zurich Cantonalbank (0.02%), Allspring Global Investments Holdings LLC (0.01%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David Y Liu, Dinesh V Ph D Patel, Harold E Selick and Sarah B Noonberg.
View institutional ownership trends
.

How do I buy shares of Protagonist Therapeutics?

Shares of PTGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Protagonist Therapeutics' stock price today?

One share of PTGX stock can currently be purchased for approximately $14.53.

How much money does Protagonist Therapeutics make?

Protagonist Therapeutics (NASDAQ:PTGX) has a market capitalization of $714.88 million and generates $27.36 million in revenue each year. The company earns $-125,550,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis.

How many employees does Protagonist Therapeutics have?

The company employs 118 workers across the globe.

How can I contact Protagonist Therapeutics?

Protagonist Therapeutics' mailing address is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560. The official website for the company is www.protagonist-inc.com. The company can be reached via phone at (510) 474-0170 or via email at bkorb@soleburytrout.com.

This page (NASDAQ:PTGX) was last updated on 2/2/2023 by MarketBeat.com Staff